DE60004052D1 - Pharmazeutische zubereitungen auf der basis von levodopa, carbidopa und entacapone - Google Patents

Pharmazeutische zubereitungen auf der basis von levodopa, carbidopa und entacapone

Info

Publication number: DE60004052D1
Authority: DE; Germany
Prior art keywords: entacapone; carbidopa; levodopa; pharmaceutical preparations; preparations based
Prior art date: 1999-06-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60004052T

Other languages

English (en)

Other versions

DE60004052T2 (de

Inventor

Sari Kallioinen

Lasse Kervinen

Marja Laaksonen

Jarmo Lintulaakso

Mervi Niskanen

Marja Partanen

Marja Ritala

Kari Vahervuo

Matti Virkki

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Orion Oyj

Original Assignee

Orion Oyj

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-30

Filing date

2000-06-29

Publication date

2003-08-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8554988&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60004052(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-29 Application filed by Orion Oyj filed Critical Orion Oyj

2003-08-28 Publication of DE60004052D1 publication Critical patent/DE60004052D1/de

2004-04-15 Application granted granted Critical

2004-04-15 Publication of DE60004052T2 publication Critical patent/DE60004052T2/de

2020-06-30 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
229960004205 carbidopa Drugs 0.000 title 1
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 title 1
JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 title 1
229960003337 entacapone Drugs 0.000 title 1
229960004502 levodopa Drugs 0.000 title 1
239000000825 pharmaceutical preparation Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

DE60004052T 1999-06-30 2000-06-29 Pharmazeutische zubereitungen auf der basis von levodopa, carbidopa und entacapone Expired - Lifetime DE60004052T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FI991485		1999-06-30
FI991485A FI109453B (fi)	1999-06-30	1999-06-30	Farmaseuttinen koostumus
PCT/FI2000/000593 WO2001001984A1 (en)	1999-06-30	2000-06-29	Levodopa / carbidopa / entacapone pharmaceutical preparation

Publications (2)

Publication Number	Publication Date
DE60004052D1 true DE60004052D1 (de)	2003-08-28
DE60004052T2 DE60004052T2 (de)	2004-04-15

Family

ID=8554988

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60004052T Expired - Lifetime DE60004052T2 (de)	1999-06-30	2000-06-29	Pharmazeutische zubereitungen auf der basis von levodopa, carbidopa und entacapone

Country Status (42)

Country	Link
US (2)	US6500867B1 (de)
EP (1)	EP1189608B1 (de)
JP (2)	JP4204783B2 (de)
KR (1)	KR100905428B1 (de)
CN (1)	CN1168440C (de)
AR (1)	AR033796A1 (de)
AT (1)	ATE245417T1 (de)
AU (1)	AU765932B2 (de)
BG (1)	BG65364B1 (de)
BR (2)	BRPI0011867B8 (de)
CA (1)	CA2378469C (de)
CO (1)	CO5180579A1 (de)
CZ (2)	CZ304416B6 (de)
DE (1)	DE60004052T2 (de)
DK (1)	DK1189608T3 (de)
EA (1)	EA004503B1 (de)
EE (1)	EE05473B1 (de)
ES (1)	ES2203495T3 (de)
FI (1)	FI109453B (de)
FR (1)	FR2797587A1 (de)
GE (1)	GEP20043314B (de)
HK (1)	HK1047040B (de)
HR (1)	HRP20020088B1 (de)
HU (1)	HU230395B1 (de)
IL (1)	IL146807A (de)
IT (1)	ITMI20001450A1 (de)
ME (1)	ME00520B (de)
MX (1)	MXPA01013167A (de)
MY (1)	MY127685A (de)
NO (2)	NO330260B1 (de)
NZ (1)	NZ515780A (de)
PE (1)	PE20010399A1 (de)
PL (1)	PL197818B1 (de)
PT (1)	PT1189608E (de)
RS (1)	RS50368B (de)
SI (1)	SI1189608T1 (de)
SK (1)	SK286451B6 (de)
TR (1)	TR200103763T2 (de)
TW (1)	TWI241187B (de)
UA (1)	UA75047C2 (de)
WO (1)	WO2001001984A1 (de)
ZA (1)	ZA200109868B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI109453B (fi) *	1999-06-30	2002-08-15	Orion Yhtymae Oyj	Farmaseuttinen koostumus
US20050147670A1 (en) *	2002-05-29	2005-07-07	Impax Laboratories Inc.	Oral disintegrating dosage forms
US20040166159A1 (en) *	2002-05-29	2004-08-26	Chien-Hsuan Han	Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20030224045A1 (en) *	2002-05-29	2003-12-04	Chien-Hsuan Han	Combination immediate release sustained release levodopa/carbidopa dosage forms
US20060013875A1 (en) *	2002-05-29	2006-01-19	Impax Laboratories, Inc.	Combination immediate release controlled release levodopa/carbidopa dosage forms
US7094427B2 (en) *	2002-05-29	2006-08-22	Impax Laboratories, Inc.	Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040006072A1 (en) *	2002-06-25	2004-01-08	Franz Robert M.	Sustained-release alprazolam composition
AU2003282603A1 (en) *	2002-10-11	2004-05-04	Depomed Development Ltd	Gastro-retentive levodopa delivery form
AR044007A1 (es)	2003-04-11	2005-08-24	Newron Pharmaceuticals Inc	Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (de) *	2004-04-22	2005-10-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamidderivate zur Behandlung des Restless-Leg-Syndroms und der Suchterkrankungen
SE0401842D0 (sv) *	2004-07-12	2004-07-12	Dizlin Medical Design Ab	Infusion and injection solution of levodopa
WO2006037061A2 (en) *	2004-09-28	2006-04-06	Farouk Karoum	Compositions and methods of using d-dopa to treat parkinson's disease
WO2006051154A1 (en)	2004-11-10	2006-05-18	Orion Corporation	Treatment of restless legs syndrome
MX2007015377A (es) *	2005-06-08	2008-02-14	Orion Corp	Forma de dosificacion oral.
AU2012216377C1 (en) *	2005-06-08	2013-10-10	Orion Corporation	Oral dosage form
CA2613631A1 (en) *	2005-06-23	2007-01-04	Spherics, Inc.	Improved dosage forms for movement disorder treatment
MY148644A (en)	2005-07-18	2013-05-15	Orion Corp	New pharmaceutical compounds
CA2616377C (en)	2005-07-26	2014-04-01	David Alexander Learmonth	Nitrocatechol derivatives as comt inhibitors
US8877802B2 (en) *	2005-07-28	2014-11-04	Duke Univerity	Antiparkinsonian action of phenylisopropylamines
US20090012170A1 (en) *	2005-09-21	2009-01-08	Helena Nissinen	Treatment of symptoms of motor dysfunction
EP1945188A2 (de) *	2005-11-07	2008-07-23	Teva Pharmaceutical Industries Ltd.	Levodopa-zusammensetzung
WO2007069274A2 (en) *	2005-11-09	2007-06-21	Torrent Pharmaceuticals Limited	Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
GB2429645A (en) *	2006-03-10	2007-03-07	Sekhsaria Chemicals Ltd	Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
CN100384411C (zh) *	2006-03-17	2008-04-30	北京科信必成医药科技发展有限公司	卡左双多巴口腔崩解片
WO2007113371A1 (en) *	2006-03-31	2007-10-11	Iprbox Oy	Pharmaceutical composition and preparation method thereof
EP1845097A1 (de)	2006-04-10	2007-10-17	Portela & Ca., S.A.	Oxadiazolderivate als COMT Inihibitoren
EP1870097A1 (de) *	2006-06-15	2007-12-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamidederivate zur Behandlung von kognitiven Störungen
US8106056B2 (en) *	2006-06-16	2012-01-31	Solvay Pharmaceuticals B.V.	Combination preparations comprising bifeprunox and a dopamine agonist
US20080131492A1 (en) *	2006-06-23	2008-06-05	Spherics, Inc.	Dosage forms for movement disorder treatment
EP2104424A4 (de)	2006-10-30	2011-06-15	Wockhardt Research Center	Pharmazeutische zusammensetzungen mit entacapon, levodopa und carbidopa
AU2007338631A1 (en) *	2006-12-22	2008-07-03	Combinatorx, Incorporated	Pharmaceutical compositions for treatment of parkinson's disease and related disorders
US20100104634A1 (en) *	2006-12-27	2010-04-29	Mahesh Rameshwar Kalantri	Pharmaceutical compositions of entacapone
EP1946756A1 (de) *	2007-01-17	2008-07-23	Revotar Biopharmaceuticals AG	Verwendung von Entacapon für kosmetische, dermatologische und pharmazeutische Zusammensetzungen
MX2009008051A (es)	2007-01-31	2009-08-12	Bial Portela & Ca Sa	Regimen posologico para inhibidores de comt.
US20110171275A1 (en) *	2007-08-20	2011-07-14	Team Academy Of Pharmaceutical Science	Gastroretentive drug delivery system, preparation method and use thereof
BRPI0908052A2 (pt) *	2008-02-06	2015-08-11	Wockhardt Research Center	Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada
ATE534382T1 (de) *	2008-02-06	2011-12-15	Wockhardt Ltd	Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon
MX2010009610A (es)	2008-03-17	2010-09-30	Bial Portela & Ca Sa	Formas de cristal de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3 -il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol.
AU2009283813B2 (en) *	2008-08-22	2015-02-19	Wockhardt Research Centre	An extended release pharmaceutical composition of entacapone or salts thereof
CA2735050C (en) *	2008-08-22	2016-07-26	Wockhardt Research Centre	Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
TR200806646A2 (tr) *	2008-09-03	2009-06-22	Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş.	Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (de)	2009-03-23	2010-09-29	Laboratorios Lesvi, S.L.	Pharmazeutische Verbindung mit Levodopa, Entacapon und Carbidopa
EP2413912B1 (de)	2009-04-01	2019-03-13	Bial-Portela & CA, S.A.	Pharmazeutische formulierungen mit nitrocatechol-derivaten und herstellungsverfahren dafür
RU2559083C9 (ru) *	2009-05-19	2016-01-20	Неуродерм Лтд	Композиции для непрерывного введения ингибиторов допа-декарбоксилазы
US9750702B2 (en)	2009-12-25	2017-09-05	Innopharmax, Inc.	Pharmaceutical composition for treating parkinson's disease and preparation method thereof
KR101868326B1 (ko) *	2010-03-04	2018-06-19	오리온 코포레이션	파킨슨병의 치료를 위한 레보도파, 카르비도파 및 엔타카폰의 용도
DE102010023828A1 (de) *	2010-06-15	2011-12-15	IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH	Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
DK2640358T3 (en) *	2010-11-15	2018-04-16	Neuroderm Ltd	CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA-DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS THEREOF
US20140045900A1 (en) *	2011-02-11	2014-02-13	Bial-Portela & Ca, S.A.	Administration regime for nitrocatechols
EP2508174A1 (de)	2011-04-06	2012-10-10	Ljiljana Sovic Brkicic	Pharmazeutische Zusammensetzung
WO2012147099A1 (en) *	2011-04-25	2012-11-01	Suven Nishtaa Pharma Pvt. Ltd.	Pharmaceutical compositions of levodopa, carbidopa and entacapone
KR101807907B1 (ko) *	2011-04-26	2017-12-11	이노파막스, 인크.	엔타카폰의 조성물
JP6456143B2 (ja)	2011-12-13	2019-01-23	ノヴィファーマ，エス．アー．	カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
TR201204839A2 (tr)	2012-04-25	2012-12-21	Ali̇ Rai̇f İlaç Sanayi̇ A.Ş.	Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
EP2854764B1 (de)	2012-06-05	2018-12-12	Neuroderm Ltd	Zusammensetzungen mit apomorphin und organischen säuren und verwendungen davon
AU2014229127B2 (en) *	2013-03-13	2018-04-05	Neuroderm Ltd	Method for treatment of parkinson's disease
EP2799065A1 (de) *	2013-04-30	2014-11-05	Deva Holding Anonim Sirketi	Levodopa Carbidopa Entacapon Pharmazeutische Formulierungsbeispiele
US10987313B2 (en)	2013-10-07	2021-04-27	Impax Laboratories, Llc	Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3054929B1 (de)	2013-10-07	2020-08-05	Impax Laboratories, LLC	Mukoadhäsive levodopa-formulierungen mit gesteuerter freisetzung und/oder levodopa-ester und verwendungen davon
US10258585B2 (en)	2014-03-13	2019-04-16	Neuroderm, Ltd.	DOPA decarboxylase inhibitor compositions
ES2967693T3 (es)	2014-03-13	2024-05-03	Neuroderm Ltd	Composiciones del inhibidor de la dopa descarboxilasa
PT3782617T (pt)	2014-09-04	2024-02-29	Lobsor Pharmaceuticals Ab	Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona
WO2016083863A1 (en)	2014-11-28	2016-06-02	Bial - Portela & Ca, S.A.	Medicaments for slowing parkinson's disease
WO2016101969A1 (en)	2014-12-23	2016-06-30	Pharmathen S.A.	Levodopa/carbidopa/entacapone pharmaceutical preparation and method for preparing the same
WO2017039525A1 (en)	2015-09-04	2017-03-09	Lobsor Pharmaceuticals Aktiebolag	Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
CA3030089C (en) *	2016-07-11	2024-04-23	Contera Pharma Aps	Pulsatile drug delivery system for treating morning akinesia
ES2895054T3 (es)	2016-08-18	2022-02-17	Ilko Ilac Sanayi Ve Ticaret Anonim Sirketi	Fórmula de comprimido antiparkinson con perfil de disolución mejorado
WO2019145773A1 (en)	2017-12-15	2019-08-01	Nos Life Sciences Corporation	Liposomal-encapsulated formulations
AU2019237857A1 (en)	2018-03-23	2020-10-08	Lobsor Pharmaceuticals Aktiebolag	Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
US11331293B1 (en)	2020-11-17	2022-05-17	Neuroderm, Ltd.	Method for treatment of Parkinson's disease
US11844754B2 (en)	2020-11-17	2023-12-19	Neuroderm, Ltd.	Methods for treatment of Parkinson's disease
US11213502B1 (en)	2020-11-17	2022-01-04	Neuroderm, Ltd.	Method for treatment of parkinson's disease
US11986449B2 (en)	2020-12-22	2024-05-21	Amneal Pharmaceuticals Llc	Levodopa dosing regimen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4190672A (en)	1978-09-01	1980-02-26	Stanley Fahn	Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
GB8521350D0 (en) *	1985-08-28	1985-10-02	Euro Celtique Sa	Analgesic composition
US5236952A (en)	1986-03-11	1993-08-17	Hoffmann-La Roche Inc.	Catechol derivatives
NZ220599A (en) *	1986-06-16	1990-10-26	Merck & Co Inc	Controlled release oral dosage formulation of carbidopa and levodopa
US5283352A (en)	1986-11-28	1994-02-01	Orion-Yhtyma Oy	Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE4101873C2 (de)	1991-01-23	1993-12-09	Isis Pharma Gmbh	Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5888534A (en)	1995-06-13	1999-03-30	Pentech Pharmaceuticals, Inc.	Controlled release of drugs delivered by sublingual or buccal administration
GB2321190B (en) *	1997-01-16	2000-09-20	Britannia Pharmaceuticals Ltd	Pharmaceutical composition
US6599530B2 (en)	1998-09-14	2003-07-29	Orion Corporation	Oral compacted composition comprising catechol derivatives
FI109453B (fi)	1999-06-30	2002-08-15	Orion Yhtymae Oyj	Farmaseuttinen koostumus

1999
- 1999-06-30 FI FI991485A patent/FI109453B/fi not_active IP Right Cessation
2000
- 2000-05-26 TW TW089110218A patent/TWI241187B/zh not_active IP Right Cessation
- 2000-06-27 PE PE2000000641A patent/PE20010399A1/es not_active IP Right Cessation
- 2000-06-28 IT IT2000MI001450A patent/ITMI20001450A1/it unknown
- 2000-06-29 TR TR2001/03763T patent/TR200103763T2/xx unknown
- 2000-06-29 ES ES00944070T patent/ES2203495T3/es not_active Expired - Lifetime
- 2000-06-29 EA EA200200106A patent/EA004503B1/ru not_active IP Right Cessation
- 2000-06-29 AU AU58306/00A patent/AU765932B2/en not_active Expired
- 2000-06-29 CN CNB008095868A patent/CN1168440C/zh not_active Expired - Lifetime
- 2000-06-29 AT AT00944070T patent/ATE245417T1/de active
- 2000-06-29 BR BRPI0011867A patent/BRPI0011867B8/pt unknown
- 2000-06-29 JP JP2001507476A patent/JP4204783B2/ja not_active Expired - Lifetime
- 2000-06-29 AR ARP000103325A patent/AR033796A1/es unknown
- 2000-06-29 US US09/605,529 patent/US6500867B1/en not_active Expired - Lifetime
- 2000-06-29 PT PT00944070T patent/PT1189608E/pt unknown
- 2000-06-29 EE EEP200100716A patent/EE05473B1/xx unknown
- 2000-06-29 HU HU0202273A patent/HU230395B1/hu unknown
- 2000-06-29 UA UA2002010771A patent/UA75047C2/uk unknown
- 2000-06-29 CZ CZ2011-885A patent/CZ304416B6/cs not_active IP Right Cessation
- 2000-06-29 WO PCT/FI2000/000593 patent/WO2001001984A1/en active Application Filing
- 2000-06-29 GE GE4619A patent/GEP20043314B/en unknown
- 2000-06-29 RS YUP-925/01A patent/RS50368B/sr unknown
- 2000-06-29 BR BR0011867-2A patent/BR0011867A/pt not_active IP Right Cessation
- 2000-06-29 KR KR1020017015737A patent/KR100905428B1/ko active IP Right Grant
- 2000-06-29 ME MEP-2008-863A patent/ME00520B/me unknown
- 2000-06-29 SI SI200030190T patent/SI1189608T1/xx unknown
- 2000-06-29 CO CO00048944A patent/CO5180579A1/es active IP Right Grant
- 2000-06-29 DK DK00944070T patent/DK1189608T3/da active
- 2000-06-29 DE DE60004052T patent/DE60004052T2/de not_active Expired - Lifetime
- 2000-06-29 CA CA002378469A patent/CA2378469C/en not_active Expired - Lifetime
- 2000-06-29 MY MYPI20002972A patent/MY127685A/en unknown
- 2000-06-29 CZ CZ20014636A patent/CZ303010B6/cs not_active IP Right Cessation
- 2000-06-29 NZ NZ515780A patent/NZ515780A/en not_active IP Right Cessation
- 2000-06-29 PL PL352775A patent/PL197818B1/pl unknown
- 2000-06-29 MX MXPA01013167A patent/MXPA01013167A/es active IP Right Grant
- 2000-06-29 EP EP00944070A patent/EP1189608B1/de not_active Expired - Lifetime
- 2000-06-29 SK SK1923-2001A patent/SK286451B6/sk not_active IP Right Cessation
- 2000-06-30 FR FR0008472A patent/FR2797587A1/fr not_active Withdrawn
2001
- 2001-11-29 IL IL146807A patent/IL146807A/en active IP Right Grant
- 2001-11-29 ZA ZA200109868A patent/ZA200109868B/xx unknown
- 2001-12-18 NO NO20016203A patent/NO330260B1/no not_active IP Right Cessation
- 2001-12-20 BG BG106251A patent/BG65364B1/bg unknown
2002
- 2002-01-29 HR HR20020088A patent/HRP20020088B1/xx not_active IP Right Cessation
- 2002-08-20 US US10/223,298 patent/US6797732B2/en not_active Expired - Lifetime
- 2002-11-29 HK HK02108609.4A patent/HK1047040B/zh not_active IP Right Cessation
2008
- 2008-03-12 JP JP2008063280A patent/JP4885896B2/ja not_active Expired - Lifetime
2011
- 2011-01-19 NO NO20110090A patent/NO20110090L/no unknown

Also Published As

Publication number	Publication date
SK286451B6 (sk)	2008-10-07
EE200100716A (et)	2003-02-17
HUP0202273A3 (en)	2002-11-28
RS50368B (sr)	2009-11-10
ITMI20001450A1 (it)	2001-12-28
ES2203495T3 (es)	2004-04-16
EA200200106A1 (ru)	2002-06-27
EE05473B1 (et)	2011-10-17
ATE245417T1 (de)	2003-08-15
EP1189608A1 (de)	2002-03-27
MXPA01013167A (es)	2002-07-02
GEP20043314B (en)	2004-02-10
NO330260B1 (no)	2011-03-14
TR200103763T2 (tr)	2002-04-22
HU230395B1 (hu)	2016-04-28
BG106251A (en)	2002-08-30
WO2001001984A1 (en)	2001-01-11
BG65364B1 (bg)	2008-04-30
SI1189608T1 (en)	2004-04-30
FI991485A0 (fi)	1999-06-30
JP2003503454A (ja)	2003-01-28
YU92501A (sh)	2004-09-03
ZA200109868B (en)	2003-05-28
JP2008156373A (ja)	2008-07-10
EA004503B1 (ru)	2004-04-29
NO20016203L (no)	2002-02-25
PL197818B1 (pl)	2008-04-30
HRP20020088A2 (en)	2005-10-31
ITMI20001450A0 (it)	2000-06-28
NZ515780A (en)	2004-06-25
FR2797587A1 (fr)	2001-02-23
IL146807A (en)	2006-10-05
HUP0202273A2 (en)	2002-10-28
BRPI0011867B1 (pt)	2019-01-08
HRP20020088B1 (en)	2007-05-31
HK1047040A1 (en)	2003-02-07
HK1047040B (zh)	2005-04-29
CA2378469A1 (en)	2001-01-11
CZ20014636A3 (cs)	2002-05-15
CO5180579A1 (es)	2002-07-30
MY127685A (en)	2006-12-29
BR0011867A (pt)	2002-03-05
NO20016203D0 (no)	2001-12-18
CN1168440C (zh)	2004-09-29
NO20110090L (no)	2002-02-25
US6500867B1 (en)	2002-12-31
SK19232001A3 (sk)	2002-06-04
DK1189608T3 (da)	2003-11-10
PL352775A1 (en)	2003-09-08
JP4204783B2 (ja)	2009-01-07
CZ304416B6 (cs)	2014-04-23
AR033796A1 (es)	2004-01-07
FI109453B (fi)	2002-08-15
PE20010399A1 (es)	2001-04-10
CN1358090A (zh)	2002-07-10
TWI241187B (en)	2005-10-11
JP4885896B2 (ja)	2012-02-29
US20030017201A1 (en)	2003-01-23
FI991485A (fi)	2000-12-31
EP1189608B1 (de)	2003-07-23
PT1189608E (pt)	2003-12-31
AU5830600A (en)	2001-01-22
UA75047C2 (en)	2006-03-15
AU765932B2 (en)	2003-10-02
CA2378469C (en)	2009-10-06
US6797732B2 (en)	2004-09-28
ME00520B (me)	2011-10-10
CZ303010B6 (cs)	2012-02-29
KR100905428B1 (ko)	2009-06-30
KR20020010155A (ko)	2002-02-02
BRPI0011867B8 (pt)	2021-05-25
DE60004052T2 (de)	2004-04-15

Legal Events

Date	Code	Title	Description
2004-07-29	8380	Miscellaneous part iii	Free format text: DER VERTRETER IST ZU BERICHTIGEN IN: WINTER, BRANDL, FURNISS, HUBNER, ROSS, KAISER, POLTE, PARTNERSCHAFT, 85354 FREISING
2004-08-19	8364	No opposition during term of opposition

Publication	Publication Date	Title
DE60004052D1 (de)	2003-08-28	Pharmazeutische zubereitungen auf der basis von levodopa, carbidopa und entacapone
EE05000B1 (et)	2008-04-15	2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
NO975513D0 (no)	1997-12-01	3-hydroksypyridin-2-karboksylsyreamidester, fremstilling og anvendelse som legemiddel
DE122007000035I1 (de)	2007-07-19	5-Alkyl-2-Arylaminophenylessigs{ure und derivative
BR9813284B1 (pt)	2012-08-21	aminoácidos cìclicos e derivados dos mesmos úteis como agentes farmacêuticos e composição farmacêutica.
IS5129A (is)	1999-07-23	Arýlsúlfonýlamínó hýdroxamsýruafleiður, notkun þeirra, ásamt lyfjablöndum
IS5130A (is)	1999-07-23	Arýlsúlfonýlamínó hýdroxamsýruafleiður, notkun þeirra, ásamt lyfjablöndum
ITMI982280A0 (it)	1998-10-23	Alcune n-(2-april-propionil)-solfonammidi e preparazioni farmaceutiche che le contengono
IS5353A (is)	2000-01-19	Asýl-píperasínil-pýrimídínafleiður, framleiðsla og notkun þeirra sem lyfja
DE69519368T2 (de)	2001-03-08	Neue antiandrogenen mitteln pharmazeutische präparate und verwendungen davon
ES1036289Y (es)	1998-01-16	Muñequera deportiva perfeccionada.
NO20000066D0 (no)	2000-01-06	6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse
ATE252553T1 (de)	2003-11-15	((aminoiminomethyl)amino) alkanecarboxamide und deren therapeutische verwendungen
PT1235809E (pt)	2004-04-30	1,2,3,4,5,6-hexa-hidro-2,6-metano-3-benzazocinas substituidas e sua utilizacao como medicamentos
ES1038353Y (es)	1999-01-16	Jeringuilla perfeccionada.
ES1039049Y (es)	1999-03-16	Jeringuilla desechable perfeccionada.
EE200200266A (et)	2003-06-16	2-arüülkinoliini derivaadid, nende valmistamine ja kasutamine ravimites
ES1037202Y (es)	1998-06-16	Jeringuilla desechable perfeccionada.
ES1037125Y (es)	1998-06-16	Vitrina-expositor perfeccionada.
ES1038808Y (es)	1999-01-16	Harinador perfeccionado.
IT243703Y1 (it)	2002-03-05	Siringa perfezionata
ES1033974Y (es)	1997-10-16	Jeringuilla perfeccionada.
ES1036920Y (es)	1998-05-01	Pulverizador perfeccionado.
ES1038640Y (es)	1999-05-16	Expositor perfeccionado.
NO981089D0 (no)	1998-03-12	Epoksy-azetidinoner, fremstilling og anvendelse derav